Hospital-Treated Gram-Negative Infections Market t
Hospital-Treated Gram-Negative
Infections Market – Industry Trends and Forecast to 2026 with key players like Lupin
Pharmaceuticals, Inc.; Istituto Lusofarmaco D'Italia S.p.A.; Adelco; Achaogen,
Inc.; ALLERGAN; MELINTA THERAPEUTICS, INC.; Polyphor Ltd.
Hospital-Treated
Gram-Negative Infections Market By Therapy (Cephalosporin, Aminoglycoside;
Ampicillin/Sulbactam, Carbapenem, Colistin or Rifampin; Aminoglycoside,
Carbapenem, Colistin, Fosfomycin, Rifampin, or Tigecycline;
Ceftolozane/Tazobactam; Ceftazidime/Avibactam; Others); Indication (NP;
cSSSIs/SSIs; BSIs; cIAIs; UTIs); Pathogen Type (Klebsiella; Acinetobacter;
Coli; Cepacia; Pseudomonas; Serratia; Enterobacter; Others); Application
(Hospitals; Labs); Geography (North America; Europe; Asia-Pacific; South
America; Middle East and Africa) – Industry Trends and Forecast to 2026
Market Analysis: Global
Hospital-Treated Gram-Negative Infections Market
Global hospital-treated
gram-negative infections market is expected to register a substantial CAGR in
the forecast period of 2021-2026. The report contains data from the base year
of 2018 and the historic year of 2017. This rise in market value can be attributed
to the continuous research and development of various pharmaceutical
organizations.
Download full sample report of Hospital-Treated Gram-Negative Infections Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hospital-treated-gram-negative-infections-market
Market Definition: Global Hospital-Treated Gram-Negative
Infections Market
Hospital-treated
gram-negative infections are microbial infections caused by different pathogens
interacting with the patient’s bloodstream through wounds, surgical sites and
other areas in a healthcare setting. These infections are caused by various
pathogens with the most common, “klebsiella”, “E.coli”, “Acinetobacter” and
various others.
Patients suffering from
gram negative infections are known to have high fever, lack of appetite, nausea
and in some extreme cases even seizures. Their treatment and removal is
achieved with the help of combination of different therapeutics and systems
inclusive of regular controlled dosage of anti-microbials with anti-biotics.
Market Drivers
Increasing rate and
prevalence of antibiotic resistance is expected to boost the growth of the
market
Lack of effectiveness in
treating of these anti-microbial infections with the help of traditional
therapeutics is expected to boost the growth of the market
Growing mortality rate
caused by anti-microbial resistance is giving rise to better therapeutic
solutions; this factor is expected to drive the growth of the market
Market Restraints
Lack in the availability
of anti-microbial agents in the form of pharmaceuticals or drug pipeline for
the treatment of gram-negative infections; this factor is expected to restrict
the growth of the market
Significant numbers of
resistance and challenges facing the companies and pharmaceuticals regarding
the development of treatment solutions; this factor is expected to restrict the
growth of the market
Segmentation: Global
Hospital-Treated Gram-Negative Infections Market
By Therapy
· Cephalosporin, Aminoglycoside
· Ampicillin/Sulbactam,
Carbapenem, Colistin or Rifampin
· Aminoglycoside, Carbapenem,
Colistin, Fosfomycin, Rifampin, or Tigecycline
· Ceftolozane/Tazobactam
· Ceftazidime/Avibactam
· Others
By Indication
· NP
· cSSSIs/SSIs
· BSIs
· cIAIs
· UTIs
By Pathogen Type
· Klebsiella
· Acinetobacter
· Coli
· Cepacia
· Pseudomonas
· Serratia
· Enterobacter
· Others
By Application
· Hospitals
· Labs
By Geography
· North America
· U.S.
· Canada
· Mexico
· Europe
· Germany
· Italy
· U.K.
· France
· Spain
· Netherlands
· Belgium
· Switzerland
· Turkey
· Russia
· Rest of Europe
· Asia-Pacific
· Japan
· China
· India
· South Korea
· Australia
· Singapore
· Malaysia
· Thailand
· Indonesia
· Philippines
· Rest of Asia-Pacific
· South America
· Brazil
· Rest of South America
· Middle East and Africa
· South Africa
· Rest of Middle East and Africa
Key Developments in the Market:
In June 2019, MELINTA
THERAPEUTICS, INC. announced that the US FDA had accepted the company’s
supplemental NDA (sNDA) for “BAXDELA (delafloxacin)” for priority review. The
application will expand the current indication application for adults with
community-acquired bacterial pneumonia (CABP). This approval is based on
positive results out of Phase III study
In October 2018,
Novartis AG announced that they had agreed with Boston Pharmaceuticals for the
development of anti-infective drug candidates included in “Novartis Infectious
Diseases” portfolio. These candidates will be designed for treatment of
anti-biotic resistance such as “gram-negative infections”. This agreement will
provide Boston Pharmaceuticals worldwide rights, wherein Novartis will receive
financial payments upfront as well as in royalties and milestone achievements
Competitive Analysis:
Global
hospital-treated gram-negative infections market is highly fragmented and
the major players have used various strategies such as new product launches,
expansions, agreements, joint ventures, partnerships, acquisitions, and others
to increase their footprints in this market. The report includes market shares
of hospital-treated gram-negative infections market for global, Europe, North
America, Asia-Pacific, South America and Middle East & Africa.
Key Market Competitors:
Few of the major
competitors currently working in the global hospital-treated gram-negative
infections market are Merck & Co., Inc.; Pfizer Inc.; Lupin Pharmaceuticals,
Inc.; Istituto Lusofarmaco D'Italia S.p.A.; Adelco; Achaogen, Inc.; ALLERGAN;
MELINTA THERAPEUTICS, INC.; Polyphor Ltd.; Shionogi Inc.; Tetraphase
Pharmaceuticals; Spero Therapeutics; AiCuris GmbH & Co. KG; Allecra
Therapeutics; SUMMIT THERAPEUTICS PLC; Curza; Boston Pharmaceuticals and
Nabriva Therapeutics plc among others.
Get full details of TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hospital-treated-gram-negative-infections-market
Reasons for Buying this Report
This
report provides pin-point analysis for changing competitive dynamics
It
provides a forward looking perspective on different factors driving or
restraining market growth
It
provides a six-year forecast assessed on the basis of how the market is
predicted to grow
It helps
in understanding the key product segments and their future
It
provides pin point analysis of changing competition dynamics and keeps you
ahead of competitors
It helps
in making informed business decisions by having complete insights of market and
by making in-depth analysis of market segments
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-hospital-treated-gram-negative-infections-market
About Us:
Data Bridge Market Research set forth itself as an unconventional
and neoteric Market research and consulting firm with unparalleled level of
resilience and integrated approaches. We are determined to unearth the best
market opportunities and foster efficient information for your business to
thrive in the market
Contact:
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com
Browse Related Reports @
PDLC (Polymer Dispersed Liquid Crystal) for
Smart Window Market
Report This Post
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.
